Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management ...

CytomX Therapeutics, Inc. is downgraded to Hold ahead of key CX-2051 Phase 1 expansion data in 1Q26. Learn more about CTMX ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind” or the 'Company'), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived ...

Celcuity Inc. soared on best-in-class Phase 3 breast cancer data. Click to see why I have a Buy rating on CELC due to data, ...

Minot Light Capital Partners, an investment management company, released its Q3 2025 investment letter. A copy of the letter ...

Medical leaders reflect on 2025’s breakthroughs in AI, early detection, preventive care, and wellness—and explain how these shifts will shape healthcare priorities in 2026.

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

Frits Stulp, Implement Consulting, says AI and global collaboration are key to addressing patent cliffs and accelerating ...

Gabapentin has soared in popularity as an alternative to opioids, but research is finding that it isn’t as safe or effective as doctors have long thought.

Learn more about whether Glaukos Corporation or Omnicell, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Minot Light Capital Partners, an investment management company, released its Q3 2025 investment letter. A copy of the letter ...